Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial
Introduction: COVID-19 is associated with a cascade of inflammatory responses potentially lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy of montelukast, a leukotriene receptor antagonist (LTRA), on laboratory parameters in COVID-19 infection. Patients an...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2024-06-01
|
| Series: | Journal of Nephropharmacology |
| Subjects: | |
| Online Access: | https://jnephropharmacology.com/PDF/npj-13-e11650.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141580802523136 |
|---|---|
| author | Morteza Pourahmad Amir Aria Mahnaz Momenzadeh Fatemeh Nikoukar Behrooz Ataei Farzin Khorvash Manizhe Shams Kiana Shahzamani Sara Nasirharandi |
| author_facet | Morteza Pourahmad Amir Aria Mahnaz Momenzadeh Fatemeh Nikoukar Behrooz Ataei Farzin Khorvash Manizhe Shams Kiana Shahzamani Sara Nasirharandi |
| author_sort | Morteza Pourahmad |
| collection | DOAJ |
| description | Introduction: COVID-19 is associated with a cascade of inflammatory responses potentially lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy of montelukast, a leukotriene receptor antagonist (LTRA), on laboratory parameters in COVID-19 infection. Patients and Methods: The current randomized clinical trial (RCT) conducted on 67 patients with moderate-to-severe COVID-19 pneumonia in 2020-2021. All patients received treatments according to the national guidelines, while the case group additionally applied 10 mg montelukast for 14 days. The clinical disease improvement and laboratory data (complete blood cells count and differentiation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) were assessed within two weeks after the infection and compared between the groups. Results: Baseline assessed parameters did not differ between the groups (P>0.05). A significant decrease in pulse rate, also in normal ranges, was notified in the montelukast-treated group compared with the baseline (P=0.001) and with controls (P=0.033); however, other vital signs were not statistically different (P>0.05). CRP (P<0.001), ESR (P=0.008), BUN (P=0.015), and AST (P<0.001) significantly decreased in the post-intervention assessment of the montelukast-treated group. The comparison of the groups in post-intervention reviews revealed significantly lower CRP (P=0.042) and D-dimer (P=0.008) in the intervention group versus controls. Conclusion: Based on the findings of this study, montelukast use with a daily dose of 10 mg for 14 days could remarkably decrease inflammatory indices in patients with COVID-19 pneumonia. Further studies on this issue are strongly recommended. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20181208041886N3, https://www.irct.ir/trial/51633; ethical code #IR.MUI.MED. REC.1399.382). |
| format | Article |
| id | doaj-art-410c7ee562af4da6b2743d3b744b72a1 |
| institution | Kabale University |
| issn | 2345-4202 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Society of Diabetic Nephropathy Prevention |
| record_format | Article |
| series | Journal of Nephropharmacology |
| spelling | doaj-art-410c7ee562af4da6b2743d3b744b72a12024-12-04T06:02:42ZengSociety of Diabetic Nephropathy PreventionJournal of Nephropharmacology2345-42022024-06-01132e11650e1165010.34172/npj.2023.11650npj-11650Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trialMorteza Pourahmad0Amir Aria1Mahnaz Momenzadeh2Fatemeh Nikoukar3Behrooz Ataei4Farzin Khorvash5Manizhe Shams6Kiana Shahzamani7Sara Nasirharandi8Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Internal Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, IranNosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, IranInfectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, IranNosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, IranDisease Control Ward, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, IranHepatitis Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, IranDepartment of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranIntroduction: COVID-19 is associated with a cascade of inflammatory responses potentially lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy of montelukast, a leukotriene receptor antagonist (LTRA), on laboratory parameters in COVID-19 infection. Patients and Methods: The current randomized clinical trial (RCT) conducted on 67 patients with moderate-to-severe COVID-19 pneumonia in 2020-2021. All patients received treatments according to the national guidelines, while the case group additionally applied 10 mg montelukast for 14 days. The clinical disease improvement and laboratory data (complete blood cells count and differentiation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) were assessed within two weeks after the infection and compared between the groups. Results: Baseline assessed parameters did not differ between the groups (P>0.05). A significant decrease in pulse rate, also in normal ranges, was notified in the montelukast-treated group compared with the baseline (P=0.001) and with controls (P=0.033); however, other vital signs were not statistically different (P>0.05). CRP (P<0.001), ESR (P=0.008), BUN (P=0.015), and AST (P<0.001) significantly decreased in the post-intervention assessment of the montelukast-treated group. The comparison of the groups in post-intervention reviews revealed significantly lower CRP (P=0.042) and D-dimer (P=0.008) in the intervention group versus controls. Conclusion: Based on the findings of this study, montelukast use with a daily dose of 10 mg for 14 days could remarkably decrease inflammatory indices in patients with COVID-19 pneumonia. Further studies on this issue are strongly recommended. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20181208041886N3, https://www.irct.ir/trial/51633; ethical code #IR.MUI.MED. REC.1399.382).https://jnephropharmacology.com/PDF/npj-13-e11650.pdfcovid-19leukotrienemontelukastviral infection |
| spellingShingle | Morteza Pourahmad Amir Aria Mahnaz Momenzadeh Fatemeh Nikoukar Behrooz Ataei Farzin Khorvash Manizhe Shams Kiana Shahzamani Sara Nasirharandi Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial Journal of Nephropharmacology covid-19 leukotriene montelukast viral infection |
| title | Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial |
| title_full | Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial |
| title_fullStr | Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial |
| title_full_unstemmed | Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial |
| title_short | Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial |
| title_sort | evaluation of the effect of montelukast drug in improving the clinical condition of patients with covid 19 in referral hospitals in isfahan a randomized clinical trial |
| topic | covid-19 leukotriene montelukast viral infection |
| url | https://jnephropharmacology.com/PDF/npj-13-e11650.pdf |
| work_keys_str_mv | AT mortezapourahmad evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT amiraria evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT mahnazmomenzadeh evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT fatemehnikoukar evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT behroozataei evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT farzinkhorvash evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT manizheshams evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT kianashahzamani evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial AT saranasirharandi evaluationoftheeffectofmontelukastdruginimprovingtheclinicalconditionofpatientswithcovid19inreferralhospitalsinisfahanarandomizedclinicaltrial |